| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 1/50 - 1/250 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | EFP; Z147; RNF147; ZNF147 |
| Entrez GeneID | 7706 |
| clone | 5B5B12 |
| WB Predicted band size | 71kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human TRIM25 (AA: 211-360) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于TRIM25抗体的3篇参考文献，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity*
**作者**：Gack MU et al.
**摘要**：该研究揭示了TRIM25通过其E3泛素连接酶活性介导RIG-I的K63位泛素化，从而激活抗病毒信号通路。文中使用TRIM25抗体进行免疫共沉淀和Western blot实验，证实了TRIG-I与TRIM25的相互作用及其在抗RNA病毒中的关键作用。
---
2. **文献名称**：*TRIM family proteins: roles in autophagy, immunity, and carcinogenesis*
**作者**：Uchil PD et al.
**摘要**：该综述总结了TRIM蛋白家族(包括TRIM25)在细胞自噬、免疫调控和癌症中的功能。其中特别提到TRIM25抗体在免疫荧光和蛋白质定位研究中的应用，强调了其在病毒感染和肿瘤微环境研究中的价值。
---
3. **文献名称**：*TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway*
**作者**：Zhang Z et al.
**摘要**：本文发现TRIM25通过调控Keap1-Nrf2通路促进肝癌细胞存活和增殖。研究利用TRIM25抗体进行免疫组化(IHC)和基因敲除实验，证明TRIM25的高表达与肝癌患者预后不良相关。
---
4. **文献名称**：*Antiviral activity of TRIM25 against influenza A virus by targeting viral ribonucleoproteins*
**作者**：Inn KS et al.
**摘要**：该研究报道TRIM25通过靶向流感病毒核糖核蛋白(vRNP)抑制病毒复制，并通过TRIM25抗体验证其在宿主细胞内的亚细胞定位及与病毒蛋白的互作机制。
---
以上文献均涉及TRIM25抗体的实验应用(如WB、IP、IHC等)，并聚焦于其在抗病毒、癌症及分子机制中的功能研究。
TRIM25 (Tripartite motif-containing 25) is a member of the TRIM family of proteins, characterized by a conserved N-terminal RBCC motif (RING, B-box, and coiled-coil domains) and a C-terminal PRY/SPRY domain. It functions as an E3 ubiquitin ligase, playing critical roles in innate immunity, antiviral defense, and cellular processes like proliferation and apoptosis. TRIM25 gained prominence for its role in the RIG-I-mediated antiviral signaling pathway, where it catalyzes K63-linked ubiquitination of RIG-I, enabling its interaction with MAVS and triggering type I interferon production. Dysregulation of TRIM25 has been implicated in viral infections, cancers (e.g., breast and ovarian cancers), and autoimmune disorders, with studies highlighting both oncogenic and tumor-suppressive functions depending on cellular context.
Antibodies targeting TRIM25 are essential tools for investigating its expression, post-translational modifications, and interactions. They are widely used in techniques such as Western blotting, immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation (ChIP). Commercial TRIM25 antibodies are typically raised against specific epitopes (e.g., human TRIM25 amino acids 50-150 or 400-500) and available in monoclonal (e.g., clone 1D4. 3A5) or polyclonal formats from hosts like rabbit or mouse. Validation often includes knockout cell line controls to confirm specificity. Research applications span virology (e.g., influenza, Zika virus studies), cancer biology (analyzing TRIM25's dual role in tumor progression), and immune signaling pathways. Key studies utilizing these antibodies have clarified TRIM25's structural domains, its competition with SARS-CoV-2 Nsp1 for RIG-I binding, and its interaction with RNA or proteins like ZAP or Ago2 in gene silencing.
×
